Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest International AIDS Vaccine Initiative Stories

2011-04-27 15:00:00

ATLANTA, April 27, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCBB: GOVXD), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced its financial results for the three months ended March 31, 2011. GeoVax reported a net loss of $606,282 for the three months ended March 31, 2011, compared to $690,789 for the same period in 2010. Net losses were partially offset by grant revenues of $893,002 and $1,338,560 for each period, respectively, related to...

2011-04-07 07:00:00

ATLANTA, April 7, 2011 /PRNewswire/ -- Harriet Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), will provide an update on the status of the Company's therapeutic and preventative HIV vaccines at the 2011 World Vaccine Conference at the Gaylord National Hotel and Convention Center in Washington DC on Thursday, April 14. Dr. Robinson's invited talk, which will run from 11:30 - 11:50 a.m., will cover the topic of recombinant viruses as vaccines. The talk...

2011-02-09 06:30:00

ATLANTA, Feb. 9, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a second clinical trial site at the Alabama Vaccine Research Clinic (AVRC) of the University of Alabama at Birmingham (UAB) to expand the company's HIV therapeutic vaccine trial. Although the GeoVax vaccines are currently being tested clinically for HIV prevention, this is the first clinical...

2011-02-07 05:00:00

LOS ANGELES, Feb. 7, 2011 /PRNewswire/ -- The Black AIDS Institute ("BAI"), the only national HIV/AIDS think tank focused exclusively on the Black community in the US, today released its 2011 State of AIDS in Black America report, Deciding Moment. 2011 marks the 30th anniversary of the AIDS epidemic in America and presents unique opportunities to curtail the HIV/AIDS pandemic, but key challenges remain to moving forward in the AIDS response in Black America. The report opens with an...

2011-01-20 07:00:00

ATLANTA, Jan. 20, 2011 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, is one of three recipients of the 2011 Georgia Bio (GaBio) Community Awards. Dr. Robinson will be honored at the GaBio Annual Awards Dinner to be held Thursday, January 20 at Atlanta's Fox Theater. Dr. Robinson is the developer of GeoVax's HIV-1 AIDS...

2010-12-08 03:19:00

SINGAPORE, Dec. 8, 2010 /PRNewswire-Asia/ -- From the 1st to the 3rd of March 2011, vaccine leaders from developing and developed world will meet at Vaccine World Summit in New Delhi. The event will be hosted by IMAPAC, in partnership with DCVMN (Developing Countries Vaccine Manufacturers Network). Participants will be discussing strategies to tackle global public health challenges including appropriate pandemic surveillance programs, low cost and fast vaccine manufacturing technologies,...

2010-12-06 14:20:00

ATLANTA, Dec. 6, 2010 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), has appointed David A. Dodd as Chairman of its Board of Directors effective January 1, 2011. Donald G. Hildebrand is stepping down as Chairman and will remain on the board as a Director and continue to serve as a consultant to the Company. Mr. Dodd, age 61, has...

2010-11-29 07:00:00

ATLANTA, Nov. 29, 2010 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), announced it was pleased to learn of the partial success observed in the recently completed Phase 2b trial of a therapeutic HIV/AIDS vaccine produced by Bionor Immuno AS of Oslo, Norway. Bionor reported success in reducing viral load (reduction in HIV virus in...

2010-11-16 07:37:00

CHICAGO, Nov. 16, 2010 /PRNewswire/ -- VaxTrac announced today that it has received a US$100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Mark Thomas, Executive Director, titled "VaxTrac Pilot Program 1 Narnaul, India." VaxTrac's project is one of 65 grants announced by the Gates Foundation in the fifth funding round of Grand Challenges Explorations, an initiative to...

2010-11-09 08:00:00

ATLANTA, Nov. 9, 2010 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTCQB / OTC Bulletin Board: GOVX), an Atlanta-based biopharmaceutical firm (the "Company" or "GeoVax") developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced its financial results for the three and nine months ended September 30, 2010. GeoVax reported a net loss of $644,666 ($0.04 per share) for the three months ended September 30, 2010, compared to $230,815 ($0.02 per...